Medicos Research Data Collection Agency
Successful Completion of Data Collection for Cancer-Associated Thrombosis Study
Dear Partners and Followers,
We are thrilled to announce a significant milestone achieved by our team at Medicos Research Data Collection Agency. We have successfully completed the data collection phase for a groundbreaking research study titled:
"Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer-Associated Thrombosis: Experience From a Resource-Limited Setting."
This study, conducted on 201 patients who were on follow-up from September 2021 to August 2023, aimed to evaluate the comparative efficacy and safety of Warfarin and Rivaroxaban in managing cancer-associated thrombosis (CAT) in resource-limited settings. The findings revealed that Rivaroxaban was more efficacious and safer than Warfarin for patients with CAT, aligning with reports from resource-abundant countries and recommendations from major international societies.
This research provides critical insights into optimizing treatment strategies for CAT, particularly in settings with limited resources, and has the potential to significantly improve patient outcomes.
For full details of the research findings, please visit: https://lnkd.in/dqxyFp7s
We would like to extend our heartfelt gratitude to Dr. Abel Tenaw and his colleagues for their exceptional collaboration and trust in our team throughout this project.
Stay updated on our latest research initiatives by joining our Telegram channel: https://t.me/medicosresearch
Transforming Data into Solutions for a Healthier Tomorrow.
Thank you for your continued support and trust in our work.
Best regards,
Medicos Research Data Collection Agency
@HakimEthio
Successful Completion of Data Collection for Cancer-Associated Thrombosis Study
Dear Partners and Followers,
We are thrilled to announce a significant milestone achieved by our team at Medicos Research Data Collection Agency. We have successfully completed the data collection phase for a groundbreaking research study titled:
"Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer-Associated Thrombosis: Experience From a Resource-Limited Setting."
This study, conducted on 201 patients who were on follow-up from September 2021 to August 2023, aimed to evaluate the comparative efficacy and safety of Warfarin and Rivaroxaban in managing cancer-associated thrombosis (CAT) in resource-limited settings. The findings revealed that Rivaroxaban was more efficacious and safer than Warfarin for patients with CAT, aligning with reports from resource-abundant countries and recommendations from major international societies.
This research provides critical insights into optimizing treatment strategies for CAT, particularly in settings with limited resources, and has the potential to significantly improve patient outcomes.
For full details of the research findings, please visit: https://lnkd.in/dqxyFp7s
We would like to extend our heartfelt gratitude to Dr. Abel Tenaw and his colleagues for their exceptional collaboration and trust in our team throughout this project.
Stay updated on our latest research initiatives by joining our Telegram channel: https://t.me/medicosresearch
Transforming Data into Solutions for a Healthier Tomorrow.
Thank you for your continued support and trust in our work.
Best regards,
Medicos Research Data Collection Agency
@HakimEthio